Santhera Pharmaceuticals Holding AG
SIX:SANN
Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft. The company went IPO on 2006-11-03. The firm is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft. The company went IPO on 2006-11-03. The firm is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Revenue Growth: Santhera reported CHF 24 million in total revenues for H1 2025, up 70% year-on-year, driven by strong product sales and royalties.
Guidance Raised: 2025 full-year revenue guidance was raised above the previous CHF 65–70 million range due to ongoing strong demand.
AGAMREE Adoption: AGAMREE achieved about 40% market share among steroid-using DMD patients in Germany and Austria, with Austria topping 50%. Over 450–500 patients started on AGAMREE in these two markets.
US & China Progress: US partner Catalyst reported USD 49.4 million in H1 2025 sales and is on track for USD 100–110 million full-year; China saw over 250 patients treated soon after launch.
Financing Secured: New CHF 20 million financing was completed to meet increased inventory needs in response to higher demand, extending runway to cash flow breakeven by mid-2026.
Operational Efficiency: Operating expenses tracked at CHF 27.3 million for H1, with full-year expected at CHF 50–55 million, in line with prior guidance.
Manufacturing Expansion: Second manufacturing site is ahead of schedule, expected to deliver first product in Q4 2025 and reduce cost of goods.
